These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH. J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192 [Abstract] [Full Text] [Related]
7. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R. J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136 [Abstract] [Full Text] [Related]
8. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP, Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators. J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511 [Abstract] [Full Text] [Related]
9. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP. J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114 [Abstract] [Full Text] [Related]
13. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D. J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689 [Abstract] [Full Text] [Related]
16. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR. Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340 [Abstract] [Full Text] [Related]
17. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825 [Abstract] [Full Text] [Related]
18. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS. Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657 [Abstract] [Full Text] [Related]